Dysregulation of the PI3K/AKT/mTOR pathway has an impact on resistance to endocrine therapy, PARP inhibitors, chemo- and targeted therapies, leading to cancer progression and poorer outcomes, and blockage of this pathway can enhance drug sensitivity and reverse resistance [5,7,8,9]. The gene discussed is AKT1; the disease is cancer.